Merck target raised to $160 after Moderna cancer therapy data
Goldman Sachs raises its price target on Merck to $160 from $140 after partner mRNA cancer therapy data involving Moderna.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.